Eledon Pharmaceuticals Statistics
Share Statistics
Eledon Pharmaceuticals has 59.74M shares outstanding. The number of shares has increased by 68.42% in one year.
| Shares Outstanding | 59.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.98% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.06M |
| Failed to Deliver (FTD) Shares | 7 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 960.55K, so 1.61% of the outstanding shares have been sold short.
| Short Interest | 960.55K |
| Short % of Shares Out | 1.61% |
| Short % of Float | 1.72% |
| Short Ratio (days to cover) | 1.45 |
Valuation Ratios
The PE ratio is -1098.91 and the forward PE ratio is -4.02.
| PE Ratio | -1098.91 |
| Forward PE | -4.02 |
| PS Ratio | 0 |
| Forward PS | 7.9 |
| PB Ratio | 6147.97 |
| P/FCF Ratio | -1121.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Eledon Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 14.41, with a Debt / Equity ratio of 0.05.
| Current Ratio | 14.41 |
| Quick Ratio | 14.41 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 5.05 |
| Cash Flow / Debt | -103.2 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -5.59% and return on capital (ROIC) is -566.46%.
| Return on Equity (ROE) | -5.59% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -566.46% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.02M |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 189.47% in the last 52 weeks. The beta is 0.77, so Eledon Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | 189.47% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 2.8 |
| Relative Strength Index (RSI) | 51.31 |
| Average Volume (20 Days) | 452.42K |
Income Statement
In the last 12 months, Eledon Pharmaceuticals had revenue of $0 and earned -$40.33M in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | -374.00K |
| Operating Income | -43.00M |
| Net Income | -40.33M |
| EBITDA | 0 |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $4.61M in cash and $383.00K in debt, giving a net cash position of $4.23M.
| Cash & Cash Equivalents | 4.61M |
| Total Debt | 383.00K |
| Net Cash | 4.23M |
| Retained Earnings | -319.40M |
| Total Assets | 114.58M |
| Working Capital | 69.02M |
Cash Flow
In the last 12 months, operating cash flow was -$39.53M and capital expenditures $0, giving a free cash flow of -$39.53M.
| Operating Cash Flow | -39.53M |
| Capital Expenditures | 0 |
| Free Cash Flow | -39.53M |
| FCF Per Share | 0 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ELDN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -15.04% |
Analyst Forecast
The average price target for ELDN is $16, which is 263.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 263.6% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 5, 2020. It was a backward split with a ratio of 1:18.
| Last Split Date | Oct 5, 2020 |
| Split Type | backward |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | -0.6 |
| Piotroski F-Score | 3 |